GPX4 and breast cancer: We found that clinically used pan-HDAC inhibitors panobinostat and vorinostat synergize with GPX4 inhibitors to induce cell death in lung, melanoma, and breast cancer persister cell models but not in parental cells (Fig. 3, A to F, and fig.